{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T23:42:37Z","timestamp":1764027757522,"version":"3.44.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.xphs.2021.11.014","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T16:20:28Z","timestamp":1637425228000},"page":"1682-1689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Isolation, Identification and Structural Verification of a Methylene-Bridged Naloxone \u201cDimer\u201d Formed by Formaldehyde"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-0434","authenticated-orcid":false,"given":"Philipp","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Philipp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-6066","authenticated-orcid":false,"given":"Hans-Christian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8855-730X","authenticated-orcid":false,"given":"Konstantin","family":"Karaghiosoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2009","series-title":"Guidelines For the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","key":"10.1016\/j.xphs.2021.11.014_bib0001"},{"key":"10.1016\/j.xphs.2021.11.014_bib0002","first-page":"1419","article-title":"Drug and opioid-involved overdose deaths \u2013 United States, 2013-2017","volume":"67","author":"Scholl","year":"2019","journal-title":"MMWR"},{"issue":"14","key":"10.1016\/j.xphs.2021.11.014_bib0003","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2146\/ajhp170560","article-title":"Nonprescription availability of the opioid antagonist naloxone","volume":"75","author":"Landers","year":"2018","journal-title":"Am. J. Health-Syst. Pharm"},{"key":"10.1016\/j.xphs.2021.11.014_bib0004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication treatment of opioid use disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.xphs.2021.11.014_bib0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0022-3565(24)38234-5","article-title":"Methadone blocks morphine tolerance and N-methyl-d-aspartate-induced hyperalgesia","volume":"289","author":"Davis","year":"1999","journal-title":"JPET"},{"issue":"CD002207","key":"10.1016\/j.xphs.2021.11.014_bib0006","first-page":"1","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2003","journal-title":"CDSR"},{"key":"10.1016\/j.xphs.2021.11.014_bib0007","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/a-1083-6842","article-title":"Therapeutic drug monitoring in buprenorphine\/naloxone treatment for opioid use disorder: clinical feasibility and optimizing assay precision","volume":"53","author":"Elarabi","year":"2020","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.xphs.2021.11.014_bib0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.xphs.2021.11.014_bib0009","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-200969050-00006","article-title":"Buprenorphine\/Naloxone: a review of its use in the treatment of opioid dependence","volume":"69","author":"Orman","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.xphs.2021.11.014_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0376-8716(03)00057-7","article-title":"Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?","volume":"70","author":"Mendelson","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.xphs.2021.11.014_bib0011","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphine\/naloxone in opioid-dependent humans","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.xphs.2021.11.014_bib0012","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1345\/aph.10421","article-title":"Opioid dependence treatment, including buprenorphine\/naloxone","volume":"36","author":"Raisch","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.xphs.2021.11.014_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4236\/pp.2019.102006","article-title":"The place of community rescue naloxone in a public health crisis of opioid overdose","volume":"10","author":"Pergolizzi","year":"2019","journal-title":"Pharmacol. Pharm"},{"key":"10.1016\/j.xphs.2021.11.014_bib0014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/2042098614564776","article-title":"Review of naloxone safety for opioid overdose: practical considerations for new technology and expanded public access","volume":"6","author":"Wermeling","year":"2015","journal-title":"Ther Adv Drug Saf"},{"issue":"10","key":"10.1016\/j.xphs.2021.11.014_bib0015","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xphs.2021.11.014_bib0016","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14740338.2019.1613372","article-title":"The role of take-home naloxone in the epidemic of opioid overdose involving illicitly manufactured fentanyl and its analogs","volume":"18","author":"Kim","year":"2019","journal-title":"Expert Opin. Drug Saf"},{"key":"10.1016\/j.xphs.2021.11.014_bib0017","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/10826070701191151","article-title":"Identification of Pharmaceutical Impurities","volume":"30","author":"Qiu","year":"2007","journal-title":"J. Liq. Chrom. Relat. Tech"},{"key":"10.1016\/j.xphs.2021.11.014_bib0018","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jpba.2005.12.033","article-title":"Simultaneous determination of formic acid and formaldehyde in pharmaceutical excipients using headspace GC\/MS","volume":"41","author":"Del Dario","year":"2006","journal-title":"J. Pharm. Biomed. Anal"},{"key":"10.1016\/j.xphs.2021.11.014_bib0019","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0536.1998.tb05805.x","article-title":"Formation of formaldehyde and peroxides by air oxidation of high polyoxyethylene surfactants","volume":"39","author":"Bergh","year":"1998","journal-title":"Contact Derm"},{"key":"10.1016\/j.xphs.2021.11.014_bib0020","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1023\/A:1018903908385","article-title":"Degradation of O6-benzylguanine in aqueous polyethhylene glycol 400 (PEG 400) solutions: concerns with formaldehyde in PEG 400","volume":"11","author":"Bindra","year":"1994","journal-title":"Pharm. Res"},{"key":"10.1016\/j.xphs.2021.11.014_bib0021","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1248\/cpb.57.1096","article-title":"Generation of Formaldehyde by pharmaceutical excipients and its absorption by meglumine","volume":"57","author":"Fujita","year":"2009","journal-title":"Chem. Pharm. Bull"},{"key":"10.1016\/j.xphs.2021.11.014_bib0022","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1081\/PDT-120030249","article-title":"Influence of formaldehyde impurity in polysorbate 80 and PEG-300 on stability of parenteral formulation of BMS-204352: identification and control of degradation product","volume":"9","author":"Nassar","year":"2004","journal-title":"Pharm. Dev. Technol"},{"key":"10.1016\/j.xphs.2021.11.014_bib0023","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0731-7085(94)90033-7","article-title":"Pharmaceutical application of LC-MS. 1 \u2013 Characterization of a famotidine degradates in a package screening study by LC-APCI MS","volume":"12","author":"Qin","year":"1994","journal-title":"J. Pharm. Biomed. Anal"},{"key":"10.1016\/j.xphs.2021.11.014_bib0024","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1021\/acs.oprd.5b00417","article-title":"NMR chemical shifts of trace impurities: industrially preferred solvents used in process and green chemistry","volume":"20","author":"Babij","year":"2016","journal-title":"Org. Process Res. Dev"},{"issue":"7","key":"10.1016\/j.xphs.2021.11.014_bib0025","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1021\/ci800058v","article-title":"Solubility challenge: can you predict solubilities of 32 molecules using a database of 100 reliable measurements?","volume":"48","author":"Llin\u00e0s","year":"2008","journal-title":"J. Chem. Inf. Moedl"},{"year":"1998","series-title":"Stabilization of Naloxonhydrochlorid","author":"Rafelsberger","key":"10.1016\/j.xphs.2021.11.014_bib0026"},{"key":"10.1016\/j.xphs.2021.11.014_bib0027","article-title":"Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum","author":"Hansen","year":"1999","journal-title":"EP 0 913 152 A1"},{"key":"10.1016\/j.xphs.2021.11.014_bib0028","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0731-7085(01)00437-X","article-title":"Isolation of a 2:1 hydrochlorothiazide-formaldehyde adduct impurity in hydrochlorothiazide drug substance by preparative chromatography and characterization by electrospray ionization LC-MS","volume":"26","author":"Franolic","year":"2001","journal-title":"J. Pharm. Biomed. Anal"},{"key":"10.1016\/j.xphs.2021.11.014_bib0029","doi-asserted-by":"crossref","unstructured":"Laforce R, Rigozzi M, Mossi W, Guainazzi P, Calderari G. Aspects of melatonin manufacturing and requirements for a reliable active component. Biol. Signals Recept. 199;8:143\u2013146.","DOI":"10.1159\/000014583"},{"key":"10.1016\/j.xphs.2021.11.014_bib0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1021\/tx970202h","article-title":"Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from l-tryptophan associated with eosinophilia-myalgia syndrome","volume":"11","author":"Williamson","year":"1998","journal-title":"Chem. Res. Toxicol"},{"key":"10.1016\/j.xphs.2021.11.014_bib0031","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.2042-7158.1998.tb02322.x","article-title":"An analytical study of the interaction of low levels of formaldehyde with active pharmaceuticals","volume":"50","author":"Stephenson","year":"1998","journal-title":"J. Pharm. Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2021.11.014_bib0032","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1134\/S1070428017050128","article-title":"Methods of synthesis of alicyclic 1,5,9Triketones. reaction of transaminomethylation","volume":"53","author":"Akimova","year":"2017","journal-title":"Russ J Org Chem"},{"key":"10.1016\/j.xphs.2021.11.014_bib0033","doi-asserted-by":"crossref","first-page":"9548","DOI":"10.1016\/j.tet.2008.07.069","article-title":"An alicyclic 1,5,9-triketone 2,6.bis[(2-oxocyclohexyl)methyl]cyclohexanone, its cyclic foem and reactions with N-nucleophiles","volume":"64","author":"Akimova","year":"2008","journal-title":"Tetrahedron"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921006377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921006377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:36:54Z","timestamp":1758361014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921006377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0022354921006377"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.11.014","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isolation, Identification and Structural Verification of a Methylene-Bridged Naloxone \u201cDimer\u201d Formed by Formaldehyde","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}